TrialBreast cancer research and treatment2022

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.

Kritika Yadav et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.